Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A12327 | Pages: 281 | Charts: NA | Tables: 222 |
The global Chronic Disease Management Market size was valued at $4.90 billion in 2021 and is projected to reach $14.88 billion by 2031, growing at a CAGR of 11.8% from 2022 to 2031. Chronic disease management is an integrated care approach to managing the illness, which includes screenings, check-ups, monitoring and coordinating treatment, and patient education. It can improve the quality of life while reducing healthcare costs. Chronic disease is generally considered a condition that lasts one year or more, requires ongoing medical attention, and/or limits a person’s daily activities. Some of the most common chronic conditions are; heart disease, hypertension (high blood pressure), chronic respiratory disease, diabetes, asthma, stroke, cancer, and others. The two main risk factors associated with chronic disease are behavioral risk factors and metabolic risk factors. The behavior risk factor involves the use of tobacco, physical inactivity, unhealthy diet, and harmful use of alcohol; whereas, the metabolic risk factors are obesity, hyperglycemia, hyperlipidemia, and elevated blood pressure
[COVIDIMPACTSTATEMENT]
The key factors that drive the growth of the chronic disease management market are the rise in the geriatric population and the increase in the prevalence of various chronic diseases such as cancer and among others. For instance, according to NCBI, chronic diseases account for about 60% of deaths and 43% of the global disease burden. In addition, according to the WHO, people of all age groups, regions, and countries are affected by non-communicable diseases (NCDs). . Moreover, the rise in the popularity of chronic disease management due to the integration of IT solutions drives the Chronic Disease Management Market growth. Furthermore, an increase in strategic initiatives such as mergers, collaborations, and acquisitions by leading players, are the key factors that provide Chronic Disease Management Market opportunity during the forecast period.
However, a lack of skilled professionals as well as a trained workforce with cross-functional skills, are expected to hinder the growth of the chronic disease management market during the forecast period.
The global Chronic Disease Management Market size was valued at $4.90 billion in 2021 and is projected to reach $14.88 billion by 2031, growing at a CAGR of 11.8% from 2022 to 2031. The Chronic Disease Management Industry is segmented on the basis of type, disease type, end user, and region. By type, the market is segmented into solutions and services. The solution segment is further classified on the basis of an on-premise solution and cloud-based solutions. On the basis of service, the segment is bifurcated into educational service, implementation service, and consultant service. On the basis of Disease Type, the segment is divided into cardiovascular disease, diabetes, cancer, asthma, a chronic obstructive pulmonary disorder, and others. On the basis of End-user, the segment is divided into providers, payers, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Type Segment review
[TYPEGRAPH]
By type, the chronic disease management market is segmented into solutions and services. The solutions segment was the highest Chronic Disease Management Market sharein 2021. Owing to the increase in awareness of the use of cloud-based and on-premise solutions in healthcare leads to the growth of the chronic disease management system and drives the growth of the market.
The services are the fastest-growing segment during the forecast period. Owing to the increase in the incidence of diseases such as diabetes, cardiovascular diseases, and other chronic diseases across the globe due to surge drives the growth of the market.
Disease indication Segment Review
[DISEASETYPEGRAPH]
By disease type, the chronic disease management market is segmented into cardiovascular disease, diabetes, cancer, asthma, a chronic obstructive pulmonary disorder, and others. The diabetes segment was the highest revenue contributor to the market, owing to rise in the prevalence of diabetes due to changes in lifestyle, unhealthy diet, physical inactivity, and obesity. The rise in prevalence of type-1 and type-2 diabetes increases the demand for disease management systems to control the prevalence of this disease are the factors that are anticipated to boost the growth of the market.
Cardiovascular is estimated to be the fastest growing segment during the chronic disease management market forecast, owing to an increase in the prevalence of cardiovascular diseases such as stroke, Aortic Aneurysm, Arrhythmia, and others driving the growth of the market.
End User Segment Review
[ENDUSERGRAPH]
By end users, the healthcare provider segment was the highest revenue contributor to the market. An increase in the prevalence of chronic diseases such as cancer, cardiovascular disease, heart disease, asthma, and chronic obstructive pulmonary disease. It increases the demand for health care services to provide better treatment options for the management of chronic diseases. This factor propels the growth of the chronic disease management market significantly.
The others is estimated to be the fastest growing segment during the chronic disease management market forecast, owing to the increase in the prevalence of chronic disease and the rise in the geriatric population drives the growth of the market
Region Segment Review
[REGIONGRAPH]
Region-wise, the chronic disease management market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The North American market was dominant, in terms of revenue among other regions in 2021, owing to the prevalence of chronic diseases such as cancer, diabetes, cardiovascular disease, heart disease, and arthritis.
Asia-Pacific is estimated to grow at the fastest rate during the forecast period. Owing to increase in the prevalence of chronic diseases such as diabetes and cancer and the rise in the geriatric population are the factors that propel the growth of the market.
Key players that operate in the chronic disease management market are ZeOmega, Health Catalyst, Cedar Gate Technologies, Cognizant, Pegasystems Inc., Epic Systems Corporation, Hinduja Global Solutions Ltd. (Bengaluru), NXGN Management, LLC, Casenet, LLC, ExlServings Holdings, Inc., cliexa, Inc., Vivify Health, Inc., Allscripts Healthcare, LLC, Infosys Limited, Medecision, Altruista Health, Koninklijke Philips N.V. (Netherlands).
Get more information on this report : Request Sample Pages
The chronic disease management market is segmented into Disease Type, Type and End User.
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in prevalence of chronic disease
3.4.1.2.Rise in geriatric populations
3.4.1.3.Significant benefits to the entire healthcare continuum
3.4.1.4.Rise in popularity of chronic disease management due to integration of IT Solutions
3.4.2.Restraints
3.4.2.1.Lack of skilled professionals
3.4.3.Opportunity
3.4.3.1.High growth potential in developing economies
3.4.4.Impact analysis
3.5.Impact analysis of COVID-19 on the Chronic Disease Management Market
CHAPTER 4:CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Solution
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market size and forecast, by solution type
4.2.4.1.On-Premise Solution
4.2.4.1.1.Market size and forecast
4.2.4.2.Cloud-based Solutions
4.2.4.2.1.Market size and forecast
4.3.Services
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.3.4.Market size and forecast, by service type
4.3.4.1.Educational Service
4.3.4.1.1.Market size and forecast
4.3.4.2.Implementation Service
4.3.4.2.1.Market size and forecast
4.3.4.3.Consultant Service
4.3.4.3.1.Market size and forecast
CHAPTER 5:CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Cardiovascular diseases
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Diabetes
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
5.4.Cancer
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
5.5.Asthma
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country
5.6.Chronic Obstructive Pulmonary Disorder
5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast, by region
5.6.3.Market analysis, by country
5.7.Others
5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast, by region
5.7.3.Market analysis, by country
CHAPTER 6:CHRONIC DISEASE MANAGEMENT MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Healthcare Providers
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Healthcare Payers
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.Others
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
CHAPTER 7:CHRONIC DISEASE MANAGEMENT MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America Chronic Disease Management Market, by Type
7.2.3.North America Chronic Disease Management Market, by Disease Type
7.2.4.North America Chronic Disease Management Market, by End user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. Chronic Disease Management Market, by Type
7.2.5.1.2.U.S. Chronic Disease Management Market, by Disease Type
7.2.5.1.3.U.S. Chronic Disease Management Market, by End user
7.2.5.2.Canada
7.2.5.2.1.Canada Chronic Disease Management Market, by Type
7.2.5.2.2.Canada Chronic Disease Management Market, by Disease Type
7.2.5.2.3.Canada Chronic Disease Management Market, by End user
7.2.5.3.Mexico
7.2.5.3.1.Mexico Chronic Disease Management Market, by Type
7.2.5.3.2.Mexico Chronic Disease Management Market, by Disease Type
7.2.5.3.3.Mexico Chronic Disease Management Market, by End user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe Chronic Disease Management Market, by Type
7.3.3.Europe Chronic Disease Management Market, by Disease Type
7.3.4.Europe Chronic Disease Management Market, by End user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany Chronic Disease Management Market, by Type
7.3.5.1.2.Germany Chronic Disease Management Market, by Disease Type
7.3.5.1.3.Germany Chronic Disease Management Market, by End user
7.3.5.2.France
7.3.5.2.1.France Chronic Disease Management Market, by Type
7.3.5.2.2.France Chronic Disease Management Market, by Disease Type
7.3.5.2.3.France Chronic Disease Management Market, by End user
7.3.5.3.UK
7.3.5.3.1.UK Chronic Disease Management Market, by Type
7.3.5.3.2.UK Chronic Disease Management Market, by Disease Type
7.3.5.3.3.UK Chronic Disease Management Market, by End user
7.3.5.4.Italy
7.3.5.4.1.Italy Chronic Disease Management Market, by Type
7.3.5.4.2.Italy Chronic Disease Management Market, by Disease Type
7.3.5.4.3.Italy Chronic Disease Management Market, by End user
7.3.5.5.Spain
7.3.5.5.1.Spain Chronic Disease Management Market, by Type
7.3.5.5.2.Spain Chronic Disease Management Market, by Disease Type
7.3.5.5.3.Spain Chronic Disease Management Market, by End user
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe Chronic Disease Management Market, by Type
7.3.5.6.2.Rest of Europe Chronic Disease Management Market, by Disease Type
7.3.5.6.3.Rest of Europe Chronic Disease Management Market, by End user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia Pacific Chronic Disease Management Market, by Type
7.4.3.Asia Pacific Chronic Disease Management Market, by Disease Type
7.4.4.Asia Pacific Chronic Disease Management Market, by End user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan Chronic Disease Management Market, by Type
7.4.5.1.2.Japan Chronic Disease Management Market, by Disease Type
7.4.5.1.3.Japan Chronic Disease Management Market, by End user
7.4.5.2.China
7.4.5.2.1.China Chronic Disease Management Market, by Type
7.4.5.2.2.China Chronic Disease Management Market, by Disease Type
7.4.5.2.3.China Chronic Disease Management Market, by End user
7.4.5.3.India
7.4.5.3.1.India Chronic Disease Management Market, by Type
7.4.5.3.2.India Chronic Disease Management Market, by Disease Type
7.4.5.3.3.India Chronic Disease Management Market, by End user
7.4.5.4.Australia
7.4.5.4.1.Australia Chronic Disease Management Market, by Type
7.4.5.4.2.Australia Chronic Disease Management Market, by Disease Type
7.4.5.4.3.Australia Chronic Disease Management Market, by End user
7.4.5.5.South-Korea
7.4.5.5.1.South-Korea Chronic Disease Management Market, by Type
7.4.5.5.2.South-Korea Chronic Disease Management Market, by Disease Type
7.4.5.5.3.South-Korea Chronic Disease Management Market, by End user
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific Chronic Disease Management Market, by Type
7.4.5.6.2.Rest of Asia-Pacific Chronic Disease Management Market, by Disease Type
7.4.5.6.3.Rest of Asia-Pacific Chronic Disease Management Market, by End user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA Chronic Disease Management Market, by Type
7.5.3.LAMEA Chronic Disease Management Market, by Disease Type
7.5.4.LAMEA Chronic Disease Management Market, by End user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil Chronic Disease Management Market, by Type
7.5.5.1.2.Brazil Chronic Disease Management Market, by Disease Type
7.5.5.1.3.Brazil Chronic Disease Management Market, by End user
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia Chronic Disease Management Market, by Type
7.5.5.2.2.Saudi-Arabia Chronic Disease Management Market, by Disease Type
7.5.5.2.3.Saudi Arabia Chronic Disease Management Market, by End user
7.5.5.3.South-Africa
7.5.5.3.1.South-Africa Chronic Disease Management Market, by Type
7.5.5.3.2.South-Africa Chronic Disease Management Market, by Disease Type
7.5.5.3.3.South-Africa Chronic Disease Management Market, by End user
7.5.5.4.Rest of LEMEA
7.5.5.4.1.Rest of LEMEA Chronic Disease Management Market, by Type
7.5.5.4.2.Rest of LAMEA Chronic Disease Management Market, by Disease Type
7.5.5.4.3.Rest of LEMEA Chronic Disease Management Market, by End user
CHAPTER 8:COMPETITION LANDSCAPE
8.1.Product mapping
8.2.Competitive dashboard
8.3.Competitive heat map
8.4.Key developments
8.5.Top player positioning of top 10 players. 2021 10 Players
CHAPTER 9:COMPANY PROFILES
9.1.ALLSCRIPTS HEALTHCARE LLC
9.1.1.Company overview
9.1.2.Key Executive
9.1.3.Company snapshot
9.1.4.Operating business segments
9.1.5.Product portfolio
9.1.6.R&D expenditure.
9.1.7.Business performance
9.2.ALTRUISTA HEALTH
9.2.1.Company overview
9.2.2.Key Executive
9.2.3.Company snapshot
9.2.4.Operating business segments
9.2.5.Product portfolio
9.2.6.Key strategic moves and developments
9.3.CASENET LLC
9.3.1.Company overview
9.3.2.Key Executive
9.3.3.Company snapshot
9.3.4.Operating business segments
9.3.5.Product portfolio
9.4.CEDAR GATE TECHNOLOGIES
9.4.1.Company overview
9.4.2.Key Executive
9.4.3.Company snapshot
9.4.4.Operating business segments
9.4.5.Product portfolio
9.5.CLIEXA INC.
9.5.1.Company overview
9.5.2.Key Executive
9.5.3.Company snapshot
9.5.4.Operating business segments
9.5.5.Product portfolio
9.6.COGNIZANT
9.6.1.Company overview
9.6.2.Key Executive
9.6.3.Company snapshot
9.6.4.Operating business segments
9.6.5.Product portfolio
9.6.6.Business performance
9.7.EPIC SYSTEMS CORPORATION
9.7.1.Company overview
9.7.2.Key Executive
9.7.3.Company snapshot
9.7.4.Operating business segments
9.7.5.Product portfolio
9.8.EXLSERVICE HOLDINGS INC.
9.8.1.Company overview
9.8.2.Key Executive
9.8.3.Company snapshot
9.8.4.Operating business segments
9.8.5.Product portfolio
9.8.6.Business performance
9.9.HEALTH CATALYST INC.
9.9.1.Company overview
9.9.2.Key Executive
9.9.3.Company snapshot
9.9.4.Operating business segments
9.9.5.Product portfolio
9.9.6.R&D expenditure.
9.9.7.Business performance
9.9.8.Key strategic moves and developments
9.10.HINDUJA GLOBAL SOLUTIONS LTD.
9.10.1.Company overview
9.10.2.Key Executive
9.10.3.Company snapshot
9.10.4.Operating business segments
9.10.5.Product portfolio
9.10.6.Business performance
9.11.INFOSYS LIMITED
9.11.1.Company overview
9.11.2.Key Executive
9.11.3.Company snapshot
9.11.4.Operating business segments
9.11.5.Product portfolio
9.11.6.R&D expenditure.
9.11.7.Business performance
9.12.KONINKLIJKE PHILIPS N.V.
9.12.1.Company overview
9.12.2.Key Executive
9.12.3.Company snapshot
9.12.4.Operating business segments
9.12.5.Product portfolio
9.12.6.R&D expenditure.
9.12.7.Business performance
9.12.8.Key strategic moves and developments
9.13.MEDECISION
9.13.1.Company overview
9.13.2.Key Executive
9.13.3.Company snapshot
9.13.4.Operating business segments
9.13.5.Product portfolio
9.13.6.Key strategic moves and developments
9.14.NGXN MANAGEMENT LLC
9.14.1.Company overview
9.14.2.Key Executive
9.14.3.Company snapshot
9.14.4.Operating business segments
9.14.5.Product portfolio
9.14.6.R&D expenditure.
9.14.7.Business performance
9.15.PEGASYSTEMS INC.
9.15.1.Company overview
9.15.2.Key Executive
9.15.3.Company snapshot
9.15.4.Operating business segments
9.15.5.Product portfolio
9.15.6.R&D expenditure.
9.15.7.Business performance
9.16.VIVIFY HEALTH
9.16.1.Company overview
9.16.2.Key Executive
9.16.3.Company snapshot
9.16.4.Operating business segments
9.16.5.Product portfolio
9.17.ZEOMEGA
9.17.1.Company overview
9.17.2.Key Executive
9.17.3.Company snapshot
9.17.4.Operating business segments
9.17.5.Product portfolio
9.17.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.CHRONIC DISEASE MANAGEMENT MARKET0, BY TYPE, 2021–2031 ($MILLION)
TABLE 02.CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTION, BY REGION, 2021–2031 ($MILLION)
TABLE 03.CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTION, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 04.CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTION, BY EUROPE, 2021–2031 ($MILLION)
TABLE 05.CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTION, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 06.CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTION, BY LAMEA, 2021–2031 ($MILLION)
TABLE 07.CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION TYPE, 2021–2031 ($MILLION)
TABLE 08.CHRONIC DISEASE MANAGEMENT MARKET FOR CLOUD-BASED SOLUTION, BY SERVICES, 2021–2031 ($MILLION)
TABLE 09.CHRONIC DISEASE MANAGEMENT MARKET FOR SERVICE, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 10.CHRONIC DISEASE MANAGEMENT MARKET FOR SERVICE, BY EUROPE, 2021–2031 ($MILLION)
TABLE 11.CHRONIC DISEASE MANAGEMENT MARKET FOR SERVICE, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 12.CHRONIC DISEASE MANAGEMENT MARKET FOR SERVICE, BY LAMEA, 2021–2031 ($MILLION)
TABLE 13.CHRONIC DISEASE MANAGEMENT MARKET, BY SERVICE TYPE, 2021–2031 ($MILLION)
TABLE 14.CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 15.CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR, BY REGION, 2021–2031 ($MILLION)
TABLE 16.CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR DISEASE, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 17.CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR DISEASE, BY EUROPE, 2021–2031 ($MILLION)
TABLE 18.CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR DISEASE, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 19.CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR, BY LAMEA, 2021–2031 ($MILLION)
TABLE 20.CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY REGION, 2021–2031 ($MILLION)
TABLE 21.CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 22.CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY EUROPE, 2021–2031 ($MILLION)
TABLE 23.CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 24.CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY LAMEA, 2021–2031 ($MILLION)
TABLE 25.CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY REGION, 2021–2031 ($MILLION)
TABLE 26.CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 27.CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY EUROPE, 2021–2031 ($MILLION)
TABLE 28.CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 29.CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY LAMEA, 2021–2031 ($MILLION)
TABLE 30.CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY REGION, 2021–2031 ($MILLION)
TABLE 31.CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 32.CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY EUROPE, 2021–2031 ($MILLION)
TABLE 33.CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 34.CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY LAMEA, 2021–2031 ($MILLION)
TABLE 35.CHRONIC DISEASE MANAGEMENT MARKET FOR COPD, BY REGION, 2021–2031 ($MILLION)
TABLE 36.CHRONIC DISEASE MANAGEMENT MARKET FOR COPD, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 37.CHRONIC DISEASE MANAGEMENT MARKET FOR COPD, BY EUROPE, 2021–2031 ($MILLION)
TABLE 38.CHRONIC DISEASE MANAGEMENT MARKET FOR COPD, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 39.CHRONIC DISEASE MANAGEMENT MARKET FOR COPD, BY LAMEA, 2021–2031 ($MILLION)
TABLE 40.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY REGION, 2021–2031 ($MILLION)
TABLE 41.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 42.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY EUROPE, 2021–2031 ($MILLION)
TABLE 43.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 44.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY LAMEA, 2021–2031 ($MILLION)
TABLE 45.CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 46.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDER, BY REGION, 2021–2031 ($MILLION)
TABLE 47.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 48.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY EUROPE, 2021–2031 ($MILLION)
TABLE 49.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 50.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY LAMEA, 2021–2031 ($MILLION)
TABLE 51.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY REGION, 2021–2031 ($MILLION)
TABLE 52.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 53.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY EUROPE, 2021–2031 ($MILLION)
TABLE 54.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 55.CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY LAMEA, 2021–2031 ($MILLION)
TABLE 56.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY REGION, 2021–2031 ($MILLION)
TABLE 57.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY NORTH-AMERICA, 2021–2031 ($MILLION)
TABLE 58.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY EUROPE, 2021–2031 ($MILLION)
TABLE 59.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY ASIA-PACIFIC, 2021–2031 ($MILLION)
TABLE 60.CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY LAMEA, 2021–2031 ($MILLION)
TABLE 61.CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2021–2031 ($MILLION)
TABLE 62.NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 63.NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 64.NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 65.NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 66.U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 67.U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 68.U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 69.CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 70.CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 71.CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 72.MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 73.MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 74.MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 75.EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 76.EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 77.EUROPE SURGERY MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 78.EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 79.GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE SOLUTION, 2021–2031 ($MILLION)
TABLE 80.GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 81.GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 82.FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 83.FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 84.FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 85.UK CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 86.UK CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 87.UK CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 88.ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 89.ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 90.ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 91.SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 92.SPAIN. CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 93.SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 94.REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 95.REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 96.REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 97.ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 98.ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 99.ASIA PACIFIC SURGERY MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 100.ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 101.JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 102.JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 103.JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 104.CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 105.CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 106.CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 107.INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 108.INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 109.INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 110.AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 111.AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 112.AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 113.SOUTH-KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 114.SOUTH-KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 115.SOUTH-KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 116.REST OF ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 117.DISEASE TYPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 118.REST OF ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 119.LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 120.LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 121.LAMEA SURGERY MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 122.LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021–2031 ($MILLION)
TABLE 123.BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 124.BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 125.BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 126.SAUDI-ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 127.SAUDI-ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 128.SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 129.SOUTH-AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 130.SOUTH-AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 131.SOUTH-AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 132.REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021–2031 ($MILLION)
TABLE 133.REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021–2031 ($MILLION)
TABLE 134.REST OF LEMEA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021–2031 ($MILLION)
TABLE 135.ALLSCRIPTS HEALTHCARE LLC: KEY EXECUTIVE
TABLE 136.ALLSCRIPTS HEALTHCARE LLC: COMPANY SNAPSHOT
TABLE 137.ALLSCRIPTS HEALTHCARE LLC: OPERATING SEGMENT
TABLE 138.ALLSCRIPTS HEALTHCARE LLC: PRODUCT PORTFOLIO
TABLE 139.ALLSCRIPTS HEALTHCARE LLC: R&D EXPENDITURE, 2019–2021
TABLE 140.ALLSCRIPTS HEALTHCARE LLC: NET SALES, 2019–2021
TABLE 141.ALTRUISTA HEALTH: KEY EXECUTIVE
TABLE 142.ALTRUISTA HEALTH: COMPANY SNAPSHOT
TABLE 143.ALTRUISTA HEALTH: OPERATING SEGMENT
TABLE 144.ALTRUISTA HEALTH: PRODUCT PORTFOLIO
TABLE 145.ALTRUISTA HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 146.CASENET LLC: KEY EXECUTIVE
TABLE 147.CASENET LLC: COMPANY SNAPSHOT
TABLE 148.CASENET LLC: OPERATING SEGMENT
TABLE 149.CASENET LLC: PRODUCT PORTFOLIO
TABLE 150.CEDAR GATE TECHNOLOGIES: KEY EXECUTIVE
TABLE 151.CEDAR GATE TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 152.CEDAR GATE TECHNOLOGIES: OPERATING SEGMENT
TABLE 153.CEDAR GATE TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 154.CLIEXA INC.: KEY EXECUTIVE
TABLE 155.CLIEXA INC.: COMPANY SNAPSHOT
TABLE 156.CLIEXA INC.: OPERATING SEGMENT
TABLE 157.CLIEXA INC.: PRODUCT PORTFOLIO
TABLE 158.COGNIZANT: KEY EXECUTIVE
TABLE 159.COGNIZANT: COMPANY SNAPSHOT
TABLE 160.COGNIZANT: OPERATING SEGMENT
TABLE 161.COGNIZANT: PRODUCT PORTFOLIO
TABLE 162.COGNIZANT: NET SALES, 2019–2021
TABLE 163.EPIC SYSTEMS CORPORATION: KEY EXECUTIVE
TABLE 164.EPIC SYSTEMS COPORATION: COMPANY SNAPSHOT
TABLE 165.EPIC SYSTEMS CORPORATION: OPERATING SEGMENT
TABLE 166.EPIC SYSTEMS CORPORATION: PRODUCT PORTFOLIO
TABLE 167.EXLSERVICE HOLDINGS INC.: KEY EXECUTIVE
TABLE 168.EXLSERVICE HOLDINGS INC.: COMPANY SNAPSHOT
TABLE 169.EXLSERVICE HOLDINGS INC.: OPERATING SEGMENT
TABLE 170.EXLSERVICE HOLDINGS INC.: PRODUCT PORTFOLIO
TABLE 171.EXLSERVICE HOLDINGS INC.: NET SALES, 2019–2021
TABLE 172.HEALTH CATALYST INC.: KEY EXECUTIVE
TABLE 173.HEALTH CATALYST INC.: COMPANY SNAPSHOT
TABLE 174.HEALTH CATALYST INC.: OPERATING SEGMENT
TABLE 175.HEALTH CATALYST INC.: PRODUCT PORTFOLIO
TABLE 176.HEALTH CATALYST INC.: R&D EXPENDITURE, 2019–2021
TABLE 177.HEALTH CATALYST INC.: NET SALES, 2019–2021
TABLE 178.HEALTH CATALYST INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 179.HINDUJA GLOBAL SOLUTIONS LTD.: KEY EXECUTIVE
TABLE 180.HINDUJA GLOBAL SOLUTIONS LTD.: COMPANY SNAPSHOT
TABLE 181.HINDUJA GLOBAL SOLUTIONS LTD.: OPERATING SEGMENT
TABLE 182.HINDUJA GLOBAL SOLUTIONS LTD.: PRODUCT PORTFOLIO
TABLE 183.HINDUJA GLOBAL SOLUTIONS LTD.: NET SALES, 2019–2021
TABLE 184.INFOSYS LIMITED: KEY EXECUTIVE
TABLE 185.INFOSYS LIMITED: COMPANY SNAPSHOT
TABLE 186.INFOSYS LIMITED: OPERATING SEGMENT
TABLE 187.INFOSYS LIMITED: PRODUCT PORTFOLIO
TABLE 188.INFOSYS LIMITED: R&D EXPENDITURE, 2019–2021
TABLE 189.INFOSYS LIMITED: NET SALES, 2019–2021
TABLE 190.KONINKILJE PHILIPS N.V.: KEY EXECUTIVE
TABLE 191.KONINKILJE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 192.KONINKILJE PHILIPS N.V.: OPERATING SEGMENT
TABLE 193.KONINKILJE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 194.KONINKILJE PHILIPS N.V.: R&D EXPENDITURE, 2019–2021
TABLE 195.KONINKILJE PHILIPS N.V.: NET SALES, 2019–2021
TABLE 196.KONINKILJE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 197.MEDECISION: KEY EXECUTIVE
TABLE 198.MEDECISION: COMPANY SNAPSHOT
TABLE 199.MEDECISION: OPERATING SEGMENT
TABLE 200.MEDECISION: PRODUCT PORTFOLIO
TABLE 201.MEDECISION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 202.NGXN MANAGEMENT LLC: KEY EXECUTIVE
TABLE 203.NGXN MANAGEMENT LLC: COMPANY SNAPSHOT
TABLE 204.NGXN MANAGEMENT LLC: OPERATING SEGMENT
TABLE 205.NGXN MANAGEMENT LLC: PRODUCT PORTFOLIO
TABLE 206.NGXN MANAGEMENT LLC: R&D EXPENDITURE, 2019–2021
TABLE 207.NGXN MANAGEMENT LLC: NET SALES, 2019–2021
TABLE 208.PEGASYSTEMS INC.: KEY EXECUTIVE
TABLE 209.PEGASYSTEMS INC.: COMPANY SNAPSHOT
TABLE 210.PEGASYSTEMS INC.: OPERATING SEGMENT
TABLE 211.PEGASYSTEMS INC.: PRODUCT PORTFOLIO
TABLE 212.PEGASYSTEMS INC.: R&D EXPENDITURE, 2019–2021
TABLE 213.PEGASYSTEMS INC.: NET SALES, 2019–2021
TABLE 214.VIVIFY HEALTH: KEY EXECUTIVE
TABLE 215.VIVIFY HEALTH: COMPANY SNAPSHOT
TABLE 216.VIVIFY HEALTH: OPERATING SEGMENT
TABLE 217.VIVIFY HEALTH: PRODUCT PORTFOLIO
TABLE 218.ZEOMEGA: KEY EXECUTIVE
TABLE 219.ZEOMEGA: COMPANY SNAPSHOT
TABLE 220.ZEOMEGA: OPERATING SEGMENT
TABLE 221.ZEOMEGA: PRODUCT PORTFOLIO
TABLE 222.ZEOMEGA: KEY STRATEGIC MOVES AND DEVELOPMENTS